DataVXACS Applied Polymer MaterialsPaper
journal article·2026-03-13

Near-Infrared Chemiluminescence Supramolecular Porphyrin Hydrogel Containing Fe/Mn Double Transition Metals for Wound Healing

Kaijia Lin, Jiaxin Yang, Ke Xu, Liping Zhang, Qian Zhang, Gelin Xu, Feng Chi, Yachao Wang, Haixing Feng, Ziwei Wang, Zihan Wu, Yanqin Fan, Chong Ma, Qian Li, Dongxia Zhu, Dongfeng Xue, Lijie Ren

ACS Applied Polymer Materials· Volume 8· Issue 5
Publisher page
Source abstract

Abstract

Near-infrared chemiluminescence (NIR CL) imaging is crucial for accurate diagnosis of wound sites, as it operates without external excitation while offering high resolution, deep-tissue penetration, and high selectivity. However, materials that can achieve NIR CL with high luminescence intensity and sensitivity while also having therapeutic effects are still scarce. Moreover, the healing of infected wounds is complicated by the dynamic demands of the wound microenvironment. Thus, there is a need for an intelligent theranostic system capable of precise and efficient RONS regulation. Thus, we integrated NIR CL imaging with a dual-responsive Fe/Mn bimetallic supramolecular porphyrin hydrogel, enabling a comprehensive diagnosis and “inside-out” therapy. Within this system, endogenous peroxynitrite (ONOO – ) activates real-time in vivo NIR CL imaging for inflammation monitoring, while endogenous H 2 O 2 triggers CO release from Mn 2 [CO] 10 to modulate inflammatory factors. The addition of an Fe/Mn bimetallic enhances NIR CL intensity by nearly 10-fold and exhibits exceptional antibacterial efficacy (>99% eradication), pro-angiogenic function, and antioxidant capacity. In vivo evaluation confirmed real-time inflammation tracking and a 95.5% wound closure rate within 12 days, achieving visualized healing via ONOO – -activated imaging. This work provides deeper insight into the treatment of bacterially infected wounds.
Source: openalex_inverted_index · Quality: baseline

Research context

Polymers

OpenAlex topics: Nanoplatforms for cancer theranostics · Wound Healing and Treatments · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurology, Institute of Translational Medicine

The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital

School of Energy Science and Technology, Henan University, 379 mingli Street, Zhengzhou, Henan Province 450046, China

Rare Earth New Materials and Components Innovation Center, Shenzhen Institute for Advanced Study

University of Electronic Science and Technology of China

Department of Neurology

Neixiang County People’s Hospital

Key Laboratory of Nanobiosensing and Nanobioanalysis at Universities of Jilin Province, Department of Chemistry, Northeast Normal University, 5268 Renmin Street, Changchun, Jilin Province 130024, China

Funding

Special Project for Research and Development in Key areas of Guangdong Province · Basic and Applied Basic Research Foundation of Guangdong Province · China Postdoctoral Science Foundation · Science, Technology and Innovation Commission of Shenzhen Municipality · Jilin Provincial Scientific and Technological Development Program · Jilin Province Development and Reform Commission · National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Shenzhen Science and Technology Innovation Program · National Science and Technology Major Project · Medical-Engineering Interdisciplinary Research Foundation of Shenzhen University · Shenzhen Clinical Research Center for Neurological Diseases · Medicine Plus Program of Shenzhen University · State Key Laboratory of Neurology and Oncology Drug Development · Team-based Medical Science Research Program · Shenzhen Talent Introduction Fund · Sino-German Mobility Programme of the National Natural Science Foundation of China

References (61)

Show source-provided references
1. 10.1016/j.ijpharm.2023.12308710.1016/j.ijpharm.2023.123087 ↗
2. 10.1016/j.cej.2024.15729910.1016/j.cej.2024.157299 ↗
3. 10.1002/advs.20210515210.1002/advs.202105152 ↗
4. 10.1016/j.jconrel.2024.05.04810.1016/j.jconrel.2024.05.048 ↗
5. 10.1002/adhm.20200226810.1002/adhm.202002268 ↗
6. 10.1002/adfm.20231237410.1002/adfm.202312374 ↗
7. 10.1038/s41589-024-01583-810.1038/s41589-024-01583-8 ↗
8. 10.1016/j.mtbio.2025.10147710.1016/j.mtbio.2025.101477 ↗
9. 10.1002/adhm.20230350110.1002/adhm.202303501 ↗
10. 10.1016/j.jconrel.2025.11459410.1016/j.jconrel.2025.114594 ↗
11. 10.1002/advs.20251378410.1002/advs.202513784 ↗
12. 10.1016/j.trac.2023.11721310.1016/j.trac.2023.117213 ↗
13. 10.1039/D2CS00799A10.1039/D2CS00799A ↗
14. 10.1021/acsami.3c0803310.1021/acsami.3c08033 ↗
15. 10.1021/acs.accounts.1c0018510.1021/acs.accounts.1c00185 ↗
16. 10.1002/anie.20221005710.1002/anie.202210057 ↗
17. 10.1002/anie.20250168110.1002/anie.202501681 ↗
18. 10.1002/advs.20250125710.1002/advs.202501257 ↗
19. 10.1021/acsnano.3c0901110.1021/acsnano.3c09011 ↗
20. 10.1002/adma.20231003310.1002/adma.202310033 ↗
21. 10.1002/smll.20240880610.1002/smll.202408806 ↗
22. 10.1002/smtd.20240209610.1002/smtd.202402096 ↗
23. 10.1002/adma.20241337110.1002/adma.202413371 ↗
24. 10.1002/advs.20240417210.1002/advs.202404172 ↗
25. 10.1007/s11426-024-2411-710.1007/s11426-024-2411-7 ↗
26. 10.1039/C9SC06310B10.1039/C9SC06310B ↗
27. 10.1002/advs.20180205010.1002/advs.201802050 ↗
28. 10.1016/j.ccr.2024.21638110.1016/j.ccr.2024.216381 ↗
29. 10.1002/adhm.20250051310.1002/adhm.202500513 ↗
30. 10.1016/j.jconrel.2023.07.01510.1016/j.jconrel.2023.07.015 ↗
31. 10.1016/j.nantod.2024.10232710.1016/j.nantod.2024.102327 ↗
32. 10.1016/j.cej.2024.15070510.1016/j.cej.2024.150705 ↗
33. 10.1016/j.cej.2024.15052310.1016/j.cej.2024.150523 ↗
34. 10.1126/sciadv.adk948510.1126/sciadv.adk9485 ↗
35. 10.1016/j.cej.2025.16346910.1016/j.cej.2025.163469 ↗
36. 10.1016/j.nantod.2021.10116210.1016/j.nantod.2021.101162 ↗
37. 10.1002/adhm.20240080910.1002/adhm.202400809 ↗
38. 10.1016/j.ccr.2020.21361010.1016/j.ccr.2020.213610 ↗
39. 10.1016/j.cej.2021.12844010.1016/j.cej.2021.128440 ↗
40. 10.1002/advs.20250239110.1002/advs.202502391 ↗
41. 10.1016/j.jmst.2024.11.04010.1016/j.jmst.2024.11.040 ↗
42. 10.1016/j.cej.2024.15810810.1016/j.cej.2024.158108 ↗
43. 10.1016/j.cclet.2025.11181710.1016/j.cclet.2025.111817 ↗
44. 10.1002/smtd.20230134910.1002/smtd.202301349 ↗
45. 10.1016/j.apsb.2023.08.01910.1016/j.apsb.2023.08.019 ↗
46. 10.1002/smll.20210228610.1002/smll.202102286 ↗
47. 10.1016/j.redox.2020.10147010.1016/j.redox.2020.101470 ↗
48. 10.1016/j.cej.2021.13191910.1016/j.cej.2021.131919 ↗
49. 10.1021/acscentsci.3c0116910.1021/acscentsci.3c01169 ↗
50. 10.1016/j.pharmthera.2023.10850210.1016/j.pharmthera.2023.108502 ↗
51. 10.1002/anie.20230252510.1002/anie.202302525 ↗
52. 10.1016/j.bioactmat.2025.06.00410.1016/j.bioactmat.2025.06.004 ↗
53. 10.1016/j.ccr.2025.21750310.1016/j.ccr.2025.217503 ↗
54. 10.1002/anie.20211617410.1002/anie.202116174 ↗
55. 10.1002/adma.20220204410.1002/adma.202202044 ↗
56. 10.1039/D0BM02028A10.1039/D0BM02028A ↗
57. 10.1002/adfm.20221274010.1002/adfm.202212740 ↗
58. 10.1016/j.cej.2024.15054510.1016/j.cej.2024.150545 ↗
59. 10.1016/j.bioactmat.2024.05.00810.1016/j.bioactmat.2024.05.008 ↗
60. 10.1016/j.matdes.2025.11485410.1016/j.matdes.2025.114854 ↗
61. 10.1002/smll.20240378110.1002/smll.202403781 ↗